A U.S. federal judge has upheld a decision by the U.S. Food and Drug Administration (FDA) to remove Eli Lilly’s weight loss and diabetes drugs, Zepbound and Mounjaro, from the list of medicines in short supply.
This ruling, made on May 7, may disappoint patients hoping for more affordable versions of these popular drugs.
The FDA’s move also affects compounding pharmacies, which had been authorized to produce large quantities of generic versions of these obesity treatments while they were classified as in shortage.
Related Topics:
How to Use L-Carnitine Injections? Detailed Instructions